Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

1. A compound of formula (I)

wherein

A 1 is alkenyl, alkyl-NH-alkyl, alkyl-NH-heteroaryl, alkylcarbonyl, carboxyalkyl, carboxycycloalkyl, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, halogen, haloalkyl, —NR 5 —[C(R 6 R 7 )], i —C(O)—R 8 , —O—[C(R 9 R 10 )] p —C(O)—R 11 , —OR 12 , —N(R 13 R 14 ), —CO 2 R 15 , —C(O)—N(R 16 R 17 ), —C(R 18 R 19 )—OR 20 , —C(R 21 R 22 )—N(R 23 R 24 ), —C(═NOH)—N(H) 2 , —C(R 18a R 19a )—C(O)N(R 23 R 24 ), or —C(R 18a R 19a )—S(O) 2 —N(R 25 R 26 );

A 2 , A 3 and A 4 are each individually hydrogen, alkenyl, alkyl, alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cyano, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocyclesulfonyl, halogen, haloalkyl, —NR 5 —[C(R 6 R 7 )] n —C(O)—R 8 , —O—[C(R 9 R 10 )] p —C(O)—R 11 , —OR 12 , —S-alkyl, —S(O)-alkyl, —N(R 13 R 14 ), —CO 2 R 15 , —C(O)—N(R 16 R 17 ),—C(R 18 R 19 )—OR 20 , —C(R 21 R 22 )—N(R 23 R 24 ), —C(═NOH)—N(H) 2 , —C(R 18a R 19a )—C(O)N(R 23 R 24 ), —S(O) 2 —N(R 25 R 26 ), or —C(R 18a R 19a )—S(O) 2 —N(R 25 R 26 );

n is 0 or 1;

p is 0 or 1;

D is —O—, —S—, —S(O)— or —S(O) 2 —;

E is arylalkyl or cycloalkylalkyl;

R 1 is hydrogen or alkyl;

R 2 is hydrogen, alkyl or cycloalkyl;

R 3 and R 4 are each independently hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl, or R 3 and R 4 taken together with the atoms to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle;

R 5 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, hydroxy, alkoxy, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 6 and R 7 are each independently hydrogen or alkyl, or R 6 and R 7 taken together with the atom to which they are attached form a ring of cycloalkyl or heterocycle;

R 8 is hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, hydroxy, alkoxy, cycloalkyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl or —N(R 27 R 28 );

R 9 and R 10 are each independently hydrogen or alkyl, or R 9 and R 10 taken together with the atom to which they are attached form a ring of cycloalkyl or heterocycle;

R 11 is hydroxy or —N(R 29 R 30 );

R 12 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, haloalkyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 13 and R 14 are each independently hydrogen, alkyl, alkylsufonyl, aryl, arylalkyl, aryloxyalkyl, arylsulfonyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl or heterocyclesulfonyl;

R 15 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 16 and R 17 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl, hydroxy, or -alkyl-C(O)N(R 201 R 202 ), or R 16 and R 17 taken together with the atom to which they are attached form a heterocycle;

R 201 and R 202 are independently hydrogen or alkyl;

R 18 , R 19 and R 20 are each independently hydrogen, alkyl, aryl, arylalkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl;

R 18a and R 19a are each independently hydrogen or alkyl;

R 21 and R 22 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylcarbonyl, arylsulfonyl, cycloalkyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl or heterocyclesulfonyl;

R 23 and R 24 are each independently hydrogen, alkyl, alkylcarbonyl, alkoxy, alkylsulfonyl, aryl, arylcarbonyl, aryloxy, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl, heterocycleoxy, heterocyclesulfonyl or hydroxy, or R 23 and R 24 taken together with the atom to which they are attached form a ring of heteroaryl or heterocycle;

R 25 and R 26 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl or hydroxy, or R 25 and R 26 taken together with the atom to which they are attached form a heterocycle;

R 27 and R 28 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl, heterocyclesulfonyl or hydroxy, or R 27 and R 28 taken together with the atom to which they are attached form a heterocycle; and

R 29 and R 30 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl, heterocyclesulfonyl or hydroxyl, or R 29 and R 30 taken together with the atom to which they are attached form a heterocycle; or a salt thereof.

2. The compound according to claim 1 , wherein A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; D is —O—; and E is arylalkyl.

3. The compound according to claim 1 , wherein A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; D is —O—; and E is cycloalkylalkyl.

4. The compound as in claim 1 , wherein A 1 is —CO 2 R 15 or —C(O)—N(R 16 R 17 ); A 2 , A 3 and A 4 are each hydrogen; and E is arylalkyl or cycloalkylalkyl.

5. The compound as in claim 1 , selected from the group consisting of

E-4-[(2-methyl-2-{[4-(trifluoromethyl)benzyl]oxy}propanoyl)amino]adamantane-1-carboxamide;

E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino}adamantane-1-carboxylic acid; and

E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide; or a salt thereof.

6. The compound as in claim 1 , that is E-4-[(2-methyl-2-{[4-(trifluoromethyl)benzyl]oxy}propanoyl)amino]adamantane-1-carboxamide; or a salt thereof.

7. The compound as in claim 1 , that is E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino adamantane-1-carboxylic acid; or a salt thereof.

8. The compound as in claim 1 , that is E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino adamantane-1-carboxamide; or a salt thereof.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) of claim 1 , in combination with a pharmaceutically suitable carrier.

10. A method of inhibiting 11-beta-hydroxysteroid dehydrogenase Type I enzyme, comprising administering to a mammal, a therapeutically effective amount of the compound of formula (I) of claim 1 .

11. A method of treating disorders in a mammal by inhibiting 11-beta-hydroxysteroid dehydrogenase Type I enzyme, comprising administering to a mammal, a therapeutically effective amount of the compound of formula (I) of claim 1 .

12. A method of treating a disorder in a mammal in need thereof by inhibiting 11-beta-hydroxysteroid dehydrogenase Type I enzyme, comprising administering to the mammal, a therapeutically effective amount of the compound of formula (I) of claim 1 , wherein the disorder is non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, onset of cognitive decline, dementia, steroid-induced acute psychosis, depression, anxiety or a condition that involves excessive glucocorticoid action.

13. A compound of formula (I)

wherein

A 1 is alkenyl, alkyl-NH-alkyl, alkyl-NH-heteroaryl, alkylcarbonyl, carboxyalkyl, carboxycycloalkyl, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, halogen, haloalkyl, —NR 5 —[C(R 6 R 7 )] n —C(O)—R 8 , —O—[C(R 9 R 10 )] p —C(O)—R 11 , —OR 12 , —N(R 13 R 14 ), —CO 2 R 15 , —C(O)—N(R 16 R 17 ), —C(R 18 R 19 )—OR 20 , —C(R 21 R 22 )—N(R 23 R 24 ), —C(═NOH)—N(H) 2 , —C(R 18a R 19a )—C(O)N(R 23 R 24 ), or —C(R 18a R 19a )—S(O) 2 —N(R 25 R 26 );

A 2 , A 3 and A 4 are each individually hydrogen, alkenyl, alkyl, alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cyano, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocyclesulfonyl, halogen, haloalkyl, —NR 5 —[C(R 6 R 7 )] n —C(O)—R 8 , —O—[C(R 9 R 10 )] p —C(O)—R 11 , —OR 12 , —S-alkyl, —S(O)-alkyl, —N(R 13 R 14 ), —CO 2 R 15 , —C(O)—N(R 16 R 17 ), —C(R 18 R 19 )—OR 20 , —C(R 21 R 22 )—N(R 23 R 24 ), —C(═NOH)—N(H) 2 , —C(R 18a R 19a )—C(O)N(R 23 R 24 ), —S(O) 2 —N(R 25 R 26 ), or —C(R 18a R 19a )—S(O) 2 —N(R 25 R 26 );

n is 0 or 1;

p is 0 or 1;

D is —O—, —S—, —S(O)— or —S(O) 2 —;

E is carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocycle, heterocyclealkyl, naphthyl or biphenyl, or R 4 and E taken together with the atoms to which they are attached form a heterocycle;

R 1 is hydrogen or alkyl;

R 2 is hydrogen, alkyl or cycloalkyl;

R 3 and R 4 are each independently hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl, or R 3 and R 4 taken together with the atoms to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle;

R 5 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, hydroxy, alkoxy, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 6 and R 7 are each independently hydrogen or alkyl, or R 6 and R 7 taken together with the atom to which they are attached form a ring of cycloalkyl or heterocycle;

R 8 is hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, hydroxy, alkoxy, cycloalkyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl or —N(R 27 R 28 );

R 9 and R 10 are each independently hydrogen or alkyl, or R 9 and R 10 taken together with the atom to which they are attached form a ring of cycloalkyl or heterocycle;

R 11 is hydroxy or —N(R 29 R 30 );

R 12 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, haloalkyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 13 and R 14 are each independently hydrogen, alkyl, alkylsufonyl, aryl, arylalkyl, aryloxyalkyl, arylsulfonyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl or heterocyclesulfonyl;

R 15 is hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl or heterocycleoxyalkyl;

R 16 and R 17 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl, hydroxy, or -alkyl-C(O)N(R 201 R 202 ), or R 16 and R 17 taken together with the atom to which they are attached form a heterocycle;

R 201 and R 202 are independently hydrogen or alkyl;

R 18 , R 19 and R 20 are each independently hydrogen, alkyl, aryl, arylalkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl;

R 18a and R 19a are each independently hydrogen or alkyl;

R 21 and R 22 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylcarbonyl, arylsulfonyl, cycloalkyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl or heterocyclesulfonyl;

R 23 and R 24 are each independently hydrogen, alkyl, alkylcarbonyl, alkoxy, alkylsulfonyl, aryl, arylcarbonyl, aryloxy, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl, heterocycleoxy, heterocyclesulfonyl or hydroxy, or R 23 and R 24 taken together with the atom to which they are attached form a ring of heteroaryl or heterocycle;

R 25 and R 26 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl or hydroxy, or R 25 and R 26 taken together with the atom to which they are attached form a heterocycle;

R 27 and R 28 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl, heterocyclesulfonyl or hydroxy, or R 27 and R 28 taken together with the atom to which they are attached form a heterocycle; and

R 29 and R 30 are each independently hydrogen, alkyl, alkoxy, alkylsufonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxy, heterocycleoxyalkyl, heterocyclesulfonyl or hydroxyl, or R 29 and R 30 taken together with the atom to which they are attached form a heterocycle; or a salt thereof.

14. The compound according to claim 13 , wherein A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; D is —O—; and E is biphenyl, cycloalkyl, heteroaryl or naphthyl.

15. The compound according to claim 13 , wherein A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; D is —O—; and E is heteroaryl.

16. The compound as in claim 13 , wherein A 1 is —CO 2 R 15 or —C(O)—N(R 16 R 17 ); A 2 , A 3 and A 4 are each hydrogen; and E is naphthyl or biphenyl.

17. The compound according to claim 13 , wherein A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen and R 3 and R 4 taken together with the atoms to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle.

18. A compound of formula (I)

wherein

A 1 is alkenyl, alkyl-NH-heteroaryl, alkylcarbonyl, carboxycycloalkyl, cycloalkyl, cycloalkylcarbonyl, aryloxyalkyl, arylcarbonyl, heteroarylalkyl, heteroaryloxyalkyl, heterocyclealkyl, heterocycleoxyalkyl, heterocyclealkyloxyalkyl, imidazolyl, tetrazolyl, —C(R 21 R 22 )—N(R 23 R 24 ), —C(═NOH)—N(H) 2 ; —C(R 18a R 19a )—C(O)N(R 23 R 24 ), or —C(R 18a R 19a )—S(O) 2 —N(R 25 R 26 );

A 2 , A 3 and A 4 , are hydrogen

D is —O—, —S—, —S(O)— or —S(O) 2 —;

E is aryl, wherein aryl is phenyl or substituted phenyl;

R 1 is hydrogen or alkyl;

R 2 is hydrogen, alkyl or cycloalkyl;

R 3 and R 4 are each independently hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl, or R 3 and R 4 taken together with the atoms to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle;

R 18a and R 19a are each independently hydrogen or alkyl;

R 201 and R 202 are independently hydrogen or alkyl;

R 21 , R 22 and R 23 are hydrogen;

R 24 is alkoxy, alkylsulfonyl, aryl, arylcarbonyl, aryloxy, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl, heterocycleoxy, heterocyclesulfonyl or hydroxy, or R 23 and R 24 taken together with the atom to which they are attached form a ring of heteroaryl or heterocycle or a salt thereof

19. The compound according to claim 13 , selected from the group consisting of

3E-4-({2-methyl-2-[(2-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1carboxylic acid;

4E-4-({2-methyl-2-[(3-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxylic acid;

5E-4-{[2-(cycloheptyloxy)-2-methylpropanoyl]amino)adamantane 1-carboxylic acid;

9E-4-({2-methyl-2-[(4-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxamide;

E-4-({2-[(5-bromopyridin-2-yl)oxy]-2-methylpropanoyl}amino)adamantane-1-carboxamide;

59(E)-4-[(2-methyl-2-{[5-(1H-pyrazol-1-yl)pyridin-2-yl]oxy}propanoyl)amino]adamantane-1-carboxamide;

71E-4-({2-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)oxy]propanoyl}amino)adamantane-1-carboxamide;

72E-4-{[2-methyl-2-(pyridin-2-yloxy)propanoyl]amino}adamantane-1-carboxamide;

E-4-[(2-{[5-(1H-imidazol-1-yl)pyridin-2-yl]oxy}-2-methylpropanoyl)amino]adamantane-1-carboxamide;

87E-4-[(2-methyl-2-{[(1S,2S)-2-methylcyclohexyl]oxy}propanoyl)amino]adamantane-1-carboxylic acid;

88E-4-({2-methyl-2-[(2-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxamide;

89E-4-{[2-(cycloheptyloxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

90E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

91E-4-({2-methyl-2-[(3-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1carboxamide;

E-4-({2-[(4,4-dimethylcyclohexyl)oxy]-2-methylpropanoyl}amino)adamantane-1-carboxylic acid;

E-4-{[2-methyl-2-(1,2,3,4-tetrahydronaphthalen-2-yloxy)propanoyl]amino}adamantane-1-carboxylic acid;

E-4-{[2-(1,1′-biphenyl -3-yloxy)-2-methylpropanoyl]amino}adamantane-1-carboxylic acid;

E-4-{[2-methyl-2-(1-naphthyloxy)propanoyl]amino}adamantane-1-carboxylic acid;

E-4-{[2-methyl-2-(2-naphthyloxy)propanoyl]amino}adamantane-1-carboxylic acid; or a salt thereof.

20. A compound selected from the group consisting of

E-4-[(2-methyl-2-{4-[(trifluoroacetyl)amino]phenoxy}propanoyl)amino]adamantane-1-carboxamide;

E-4-({244-(benzyloxy)phenoxy]-2-methylpropanoyl}amino)adamantane-1-carboxamide;

4-({[((E)-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-1-adamantyl)carbonyl]amino}methyl)benzoic acid;

E-N-[4-(aminocarbonyl)benzyl1]-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-N-[4-(aminocarbonyl)methyl1]-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}adamantine-1-carboxamide;

3-({[((E)-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-1-adamantyl)carbonyl]amino}methyl)benzoic acid;

4-{[({(E)-4-[(2-methyl-2-phenoxypropanoyl)amino]-1-adamantyl}carbonyl)amino]methyl}benzoic acid;

E-N-[4-(aminocarbonyl)benzyl1]-4-[(2-methyl-2-phenoxypropanoyl)amino]adamantane-1-carboxamide;

E-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-N-(1,3-thiazol-5-ylmethyl) adamantane -1-carboxamide;

E-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-N-(pyridin-4-ylmethyl) adamantane-1-carboxamide;

N-[(E)-5-(2-amino-2-oxoethyl)-2-adamantyl]-2-(4-chlorophenoxy)-2-methylpropanamide;

2-(4-chlorophenoxy)-2-methyl-N-[(E)-5-(2H-tetraazol-5-ylmethyl)-2-adamantyl]propanamide;

2-(4-chlorophenoxy)-2-methyl-N-{(E)-5-[(2-morpholin-4-ylethoxy)methyl1]-2-adamantyl}propanamide;

N-{(E)-5-[(Z)-amino(hydroxyimino)methyl1]-2-adamantyl}-2-(4-chlorophenoxy)-2-methylpropanamide;

2-(4-chlorophenoxy)-N-((E)-5-{[(4-methoxy-6-methylpyrimidin-2-yl)amino]methyl}-2-adamantyl)-2-methylpropanamide;

2-(4-chlorophenoxy)-N-[(E)-5-(1H-imidazol-2-yl)-2-adamantyl]-2-methylpropanamide;

2-(2-chloro-4-fluorophenoxy)-2-methyl-N-[(E)-5-(2H-tetraazol-5-yl)-2-adamantyl]propanamide;

E-N-[4-(aminosulfonyl)benzyl1]-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-N-(4-{[(methylsulfonyl)amino]carbonyl}benzyl)adamantane-1-carboxamide;

N-{(E)-5-[(aminosulfonyl)methyl1]-2-adamantyl}-2-(4-chlorophenoxy)-2-methylpropanamide;

4-[({[((E)-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-1-adamantyl)methyl]sulfonyl}amino)methyl]benzoic acid;

E-4-({2-[4-chloro-2-(pyrrolidin-1-ylsulfonyl)phenoxy]-2-methylpropanoyl}amino) adamantane-1-carboxamide:

E-4-({2-methyl-2-[4-(methylsulfonyl)phenoxy]propanoyl}amino)adamantane-1-carboxamide;

E-4-({2-methyl-2-[2-(methylsulfonyl)phenoxy]propanoyl}amino)adamantane-1-carboxamide E-4-[(2-{4-chloro-2-[(diethylamino)sulfonyl]phenoxy}-2-methylpropanoyl)amino]adamantane--carboxamide;

E-4-({2-methyl-2[4-(pyrrolidin-1-ylsulfonyl)phenoxy]propanoyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-chlorophenoxy)cyclobutyl]carbonyl}amino)adamantane-1-carboxamide;

(2E)-3-((E)-4-{[2-(4-chlorophenoxy)-2-methylpropanoyl]amino}-1-adamantyl)acrylic acid;

2-(4-chlorophenoxy)-2-methyl-N-[(E)-5-(1H-pyrazol-3-yl)-2-adamantyl]propanamide;

E-4-({2-methyl-2-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]propanoyl}amino) adamantane-1-carboxylic acid;

E-4-{[2-(4-{[(tert-butylamino)carbonyl]amino}phenoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-[(2-methyl-2-{4-[(propylsulfonyl)amino]phenoxy}propanoyl)amino]adamantane-1-carboxamide;

E-4-[(2-{4-[(3,3-dimethylbutanoyl)amino]phenoxy}-2-methylpropanoyl)amino]adamantane-1-carboxamide; and

2-[(4-methoxyphenyl)sulfonyl]-2-methyl-N-[(E)-5-(2H-tetraazol-5-yl)-2-adamantyl]propanamide; or a salt thereof

21. A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) of claim 13 , in combination with a pharmaceutically suitable carrier.

22. A method of inhibiting 11-beta-hydroxysteroid dehydrogenase Type I enzyme, comprising administering to a mammal, a therapeutically effective amount of the compound of formula (I) of claim 13 .

23. The compound according to claim 13 , that is 3E-4-({2-methyl-2-[(2-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxylic acid; or a salt thereof.

24. The compound according to claim 13 , that is 4E-4-({2-methyl-2-[(3-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxylic acid; or a salt thereof.

25. The compound according to claim 13 , that is 5E-4-{[2-(cycloheptyloxy)-2-methylpropanoyl]amino}adamantane-1-carboxylic acid; or a salt thereof.

26. The compound according to claim 13 , that is 9E-4-({2-methyl-2-[(4-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxamide; or a salt thereof.

27. The compound according to claim 13 , that is E-4-({2-[(5-bromopyridin-2-yl)oxy]-2-methylpropanoyl amino)adamantane-1-carboxamide; or a salt thereof.

28. The compound according to claim 13 , that is 59(E)-4-[(2-methyl -2-{[5-(1H-pyrazol-1-yl)pyridin-2-yl]oxy}propanoyl) amino]adamantane-1-carboxamide; or a salt thereof

29. The compound according to claim 13 , that is 71E-4-({2-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)oxy]propanoyl}amino)adamantane-1-carboxamide; or a salt thereof.

30. The compound according to claim 13 , that is 72E-4-{[2-methyl-2-(pyridin-2-yloxy)propanoyl]amino}adamantane-1-carboxamide; or a salt thereof.

31. The compound according to claim 13 , that is E-4-[(2-{[5-(1H -imidazol-1-yl)pyridin-2-yl]oxy}-2-methylpropanoyl) amino]adamantane-1-carboxamide; or a salt thereof.

32. The compound according to claim 13 , that is 87E-4-[(2-methyl-2-{[(1S ,2S)-2-methylcyclohexyl]oxy}propanoyl)amino]adamantane-1-carboxylic acid; or a salt thereof.

33. The compound according to claim 13 , that is 88E-4-({2-methyl-2-[(2-methylcyclohexyl)oxy]propanoyl}amino)adamantane-1-carboxamide; or a salt thereof.

34. The compound according to claim 13 , that is 89E-4-{[2-(cycloheptyloxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide; or a salt Thereof.

35. The compound according to claim 13 , that is 90E-4-{[2-(cyclohexylmethoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide; or a salt thereof.